Clinical Fellowships
This grant funds U.S. academic cardiology programs to train and mentor physicians in diagnosing, treating, and researching ATTR amyloidosis through multidisciplinary education and research.
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026 (Clinical Fellowships submission deadline, projected)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds support salary and fellow benefits only.
Summary: Supports U.S. academic programs to advance physician training in diagnosing and treating ATTR amyloidosis through multidisciplinary education and research.
Key Information: Only ACGME-accredited U.S. institutions with active Cardiology Fellowship Programs are eligible.
Description
Alnylam’s Clinical Fellowship Grant provides funding to U.S. academic institutions to support educational clinical programs that mentor and advance the training of physicians in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis. The program aims to foster multidisciplinary collaboration, improve early recognition of ATTR, optimize treatment pathways, and facilitate the translation of emerging science into high-quality, patient-centered care. Alnylam is not involved in the selection of individual fellows; funding is awarded directly to the institution.
